Guidance
Skip Standards and indicators submenu
Quality standards
Our quality standards set out priority areas for quality improvement. They highlight areas with identified variation in current practice.
View our quality standards
How to use our quality standards
The timeline for developing quality standards
Help us develop quality standards
Selecting and prioritising quality standards topics
About quality standards
Indicators
Our indicators measure outcomes that reflect the quality of care, or processes linked by evidence to improved outcomes.
View list of indicators
Learn about the committee that develops indicators
About indicators
Skip Life sciences submenu
Life Sciences
We offer tailored support to industry during product development. Our expertise can help you build the evidence needed to achieve market access.
View life sciences
Get support from NICE
NICE Advice service
Trusted, unrivalled expertise.
Make an enquiry
Contact us to discuss your requirements.
Innovative Licensing and Access Pathway (ILAP)
Streamlining patient access to safe, financially sustainable and innovative medicines.
Learn how we evaluate technologies
Health technology evaluation and topic selection manuals
Updated manuals for methods, processes and topic selection.
Digital health technologies
Accelerating our efforts to deliver innovation to the health and care system.
Evidence standards framework
Using the best available evidence to develop recommendations that guide decisions in health, public health and social care.
Our guidance programmes
Ensuring new technologies are clinically effective and offer economic value.
Register your product
Non-pharmaceutical
NHS Innovation Service is a clear and simple point of entry for health technologies to access support and national evaluation programmes.
Pharmaceutical
UK PharmaScan is a database of new medicines, indications and formulations in the pharmaceutical pipeline.
Find published and proposed evaluations
Diagnostics
Guidance on measurements and tests used to evaluate a patient's condition.
Medical technologies
Guidance on medical technologies put forward to NICE by manufacturers.
Technology appraisals
Guidance on new and existing medicines and treatments in the NHS.
Highly specialised technologies
Guidance on the use of highly specialised medicines and treatments.
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
Skip About submenu
About
NICE helps practitioners and commissioners get the best care to patients, fast, while ensuring value for the taxpayer.
Explore about
Our programmes
Learn about the information we produce.
Guidance
Advice
Quality standards
Indicators
Digital health
Topic selection
Get involved
Understand how decisions are made:
Attend a committee meeting
Comment on draft guidance:
Guidance in consultation
Be part of a guidance committee:
Join a committee
Help develop our products:
Register as a stakeholder
Putting you at the heart of our work:
Public involvement
What we do
Social care
Life sciences
NICE international
Patient safety
Shared decision making
View all What we do
Into practice
Social care quick guides
Measuring the use of NICE guidance
Resource planner
View all Into practice
Who we are
The board
The NICE strategy 2021 to 2026
Corporate publications
View all Who we are
- Contact us
- Jobs

Cardiovascular disease prevention

Public health guideline
Reference number: PH25
Published: 22 June 2010

Register as a stakeholder

History

Surveillance consultation

Surveillance consultation
Surveillance review proposal (PDF 396 KB)

Published:

01 June 2018
Comments form (MSWord 27 KB)

Published:

01 June 2018

Stakeholder list updated

Stakeholder list (PDF 161 KB)

Published:

29 May 2018

Surveillance consultation

Surveillance consultation
Comments form (MSWord 27 KB)

Published:

12 April 2018
Surveillance review proposal (PDF 807 KB)

Published:

12 April 2018

Review documents

Review 1 - 2014
Review proposal consultation information
Review proposal document (PDF 310 KB)

Published:

17 January 2014
Review decision (PDF 314 KB)

Published:

21 March 2014
Stakeholder comments table (PDF 381 KB)

Published:

21 March 2014

Other information

Evidence update (PDF 653 KB)

Published:

01 January 2014

Consultation on the draft guidance

Consultation on the draft guidance information
Draft guidance (PDF 498 KB)

Published:

14 October 2009
Draft guidance consultation - stakeholder response table (PDF 2.83 MB)

Published:

30 June 2010

Additional evidence consultation

Additional evidence consultation information
CVD EP 11 risk factors paradigms and pathways (PowerPoint 4.77 MB)

Published:

14 October 2009
CVD EP 12 will CVD prevention widen inequalities? (PDF 141 KB)

Published:

14 October 2009
CVD EP 13 international perspectives (PowerPoint 3.47 MB)

Published:

14 October 2009
CVD EP 14 food manufacturer's perspective (PDF 96 KB)

Published:

14 October 2009
Modelleing Strategies for primary prevention of CVD (PDF 683 KB)

Published:

14 October 2009
Additional consultation on the evidence - stakeholder comments and response table (PDF 67 KB)

Published:

15 July 2010

List of stakeholders

List of stakeholders (PDF 66 KB)

Published:

29 April 2010

Consultation on the evidence

Consultation on the evidence information
Reviews and primary studies
Prevention of CVD: review 1 - effectiveness (PDF 1.38 MB)

Published:

12 May 2009
Prevention of CVD: review 2 - effectiveness (PDF 1.05 MB)

Published:

12 May 2009
Prevention of CVD: review 3 - effectiveness (PDF 1.44 MB)

Published:

12 May 2009
Prevention of CVD: review 3 - additional papers - salt (PDF 73 KB)

Published:

12 May 2009
Prevention of CVD: review 4 - cost effectiveness (PDF 784 KB)

Published:

12 May 2009
Prevention of CVD: review 5 - qualitative studies (PDF 3.02 MB)

Published:

12 May 2009
Prevention of CVD: primary qualitative study (PDF 1.59 MB)

Published:

12 May 2009
Expert papers
Prevention of CVD: EP 1 - physical activity (PDF 62 KB)

Published:

12 May 2009
Prevention of CVD: EP 2 - Health policy analysis (PDF 54 KB)

Published:

12 May 2009
Prevention of CVD: EP 3 - salt (PDF 65 KB)

Published:

12 May 2009
Prevention of CVD: EP 4 - commercial interests (PDF 87 KB)

Published:

12 May 2009
Prevention of CVD: EP 5 - regional CVD prevention (PDF 56 KB)

Published:

12 May 2009
Prevention of CVD: EP 6a - The Co-op (PDF 35 KB)

Published:

12 May 2009
Prevention of CVD: EP 6b - The Co-op (appendix) (PDF 18 KB)

Published:

12 May 2009
Prevention of CVD: EP 7 - Heart of Mersey (PDF 72 KB)

Published:

12 May 2009
Prevention of CVD: EP 8 - Have a Heart Paisley (PDF 170 KB)

Published:

12 May 2009
Prevention of CVD: EP 9 - trans fats (PDF 54 KB)

Published:

12 May 2009
Prevention of CVD: EP 10 - saturated and unsaturated fats (PDF 66 KB)

Published:

12 May 2009
Consultation on the evidence - stakeholder comments and response table (PDF 619 KB)

Published:

15 July 2010

PDG meeting minutes

PDG meeting minutes
Minutes of PDG meeting 1 (PDF 46 KB)

Published:

28 October 2008
Minutes of PDG meeting 2 (PDF 56 KB)

Published:

01 December 2008
Minutes of PDG meeting 3 (PDF 41 KB)

Published:

13 February 2009
Minutes of PDG meeting 4 (PDF 49 KB)

Published:

05 March 2009
Minutes of PDG meeting 5 (PDF 53 KB)

Published:

30 April 2009
Minutes of PDG meeting 6 (PDF 134 KB)

Published:

31 July 2009
Minutes of PDG meeting 7 (PDF 121 KB)

Published:

31 July 2009
Minutes of PDG meeting 8 (PDF 108 KB)

Published:

18 December 2009
Minutes of PDG meeting 9 (PDF 108 KB)

Published:

18 December 2009
Minutes of PDG meeting 10 & 11 (PDF 141 KB)

Published:

12 January 2010

Programme development group

Programme development group (PDF 12 KB)

Published:

25 September 2008

Final scope

Final scope (PDF 60 KB)

Published:

11 July 2008

Draft scope consultation - stakeholder response table

Draft scope consultation - stakeholder response table (PDF 668 KB)

Published:

30 April 2010

Consultation on the draft scope

Consultation on the draft scope information
Draft scope (PDF 54 KB)

Published:

23 April 2008